Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to advance the development of PCS6422 (eniluracil) administered in combination with capecitabine, for the treatment of advanced, refractory gastrointestinal tract tumors.
Lead Product(s): Eniluracil,Capecitabine
Therapeutic Area: Oncology Product Name: PCS6422
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2024
Details:
NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated in phase 1 clinical trials for the treatment of gastrointestinal cancer.
Lead Product(s): Eniluracil,Capecitabine
Therapeutic Area: Oncology Product Name: PCS6422
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
NGC-Cap combines the administration of PCS6422, the Company’s irreversible dihydropyrimidine dehydrogenase (DPD) enzyme inhibitor, with the administration of low doses of the commonly used chemotherapy capecitabine.
Lead Product(s): Capecitabine,Eniluracil
Therapeutic Area: Oncology Product Name: NGC-Cap
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to interfere with the anticancer activity.
Lead Product(s): Eniluracil,Capecitabine
Therapeutic Area: Oncology Product Name: PCS6422
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Elion Oncology
Deal Size: $103.1 million Upfront Cash: $88.0 million
Deal Type: Licensing Agreement August 27, 2020
Details:
Under this Condition Precedent License Agreement, Aposense will grant Processa a worldwide, royalty-bearing right and license, including the right to sublicense, their next generation irinotecan cancer drug, ATT-11T, upon satisfaction of the set conditions.
Lead Product(s): Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aposense
Deal Size: $127.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 01, 2020
Details:
With input from the FDA, Processa will be designing and conducting a Phase 3 trial to evaluate the ability of PCS499 to completely close ulcers in patients with NL.
Lead Product(s): PCS499
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2020